Ossiform

Name: Ossiform
Address: Oslogade 1, Odense, 5000, DK
Telephone: +4553600670

Hjem
Danmark
Odense
Ossiform

Kontaktoplysninger, kart og anvisninger, kontaktformular, åbningstider, tjenester, stjerner, fotos, videoer og meddelelser fra Ossiform, Videnskab, teknologi og ingeniørarbejde, Oslogade 1, Odense.

Ossiform® is a British-Danish MedTech company that develops bio-integrative bone substitutes, tailored to improve bone healing outcomes, simplify complex procedures, and reduce complication rates in orthopedics and spine.

02/06/2026

How can bone-mimicking scaffolds be used in cancer research? 🦴

While cancer research has come far with the use of traditional 2D cell cultures and various animal models, three-dimensional tumor models – also called tumoroids – are an emerging tool within the field.

Tumoroids have the ability to replicate key features of the tumor micro-environment, which in turn offer a more physiologically relevant disease model that retains the biological characteristics of the primary tumor🧫

Tumoroids are typically derived from patient cancer cells or immortalized cancer cell lines and they can enable:
- Studies of tumor-matrix interactions
- Evaluation of anticancer therapies
- Investigation of metastatic mechanisms

Many solid tumors and cancer types – including breast and prostate cancer – metastasize to our bones. Yet bone metastasis remains one of the most difficult aspects of cancer biology to model in vitro due to the complexity of the tissue.
By providing a mineralized, bone-mimicking microenvironment, the P3D Scaffolds from Ossiform enable researchers to grow 3D tumoroids that accurately replicate the tumor-host tissue interactions in a physiologically relevant setting without the use of animal models🐀

Such bone cancer model makes it possible to:
- Investigate how cancer cells colonize and adapt to bone
- Study metastatic mechanisms in a controlled system
- Screen anticancer therapies with improved translational relevance

As the field moves toward scalable, human-relevant research platforms, tumoroids represent a powerful alternative to traditional 2D cultures and many animal models.

Learn more about how P3D Scaffolds and tumoroids advance bone metastasis research and therapeutic development: https://ossiform.com/how-miniature-tumors-can-be-grown-on-p3d-scaffolds-for-cancer-research/

07/05/2026

We’re excited to share that Ossiform is heading to Tennessee as part of the ABHI US Accelerator 2026!

From 11–15 May, we’ll be in Memphis and Nashville, meeting with senior leaders, innovation teams, and clinicians across leading health systems, including Baptist Memorial Health, Vanderbilt University Medical Center, LifePoint, HCA, and many more🩺

A fantastic opportunity to showcase Ossiform and explore new collaborations in the US market. Looking forward to a great week of conversations💬

30/04/2026

What have we been up to lately?
Short answer: quite a lot.

We are launching a quarterly newsletter to share what we have been working on, our progress across key initiatives, and where we are headed next. Each edition brings highlights from the past quarter and a preview of what is coming.

If you would like a closer look at how Ossiform is evolving, you are very welcome to join.

Subscribe via our website or use the form linked below to follow along 👇

Ossiform news: https://ossiform.com/press-releases-and-news/
Direct link to the sign-up form: https://2fzpgw.share-eu1.hsforms.com/2qMP6Ooe5RPmoUKvvUC9gbA

28/04/2026

From bench to bedside – 3D printing in action.

What began as early validation of Ossiform’s proprietary 3D printing technology eventually led to the launch of our bone-mimicking 3D cell culture systems, the P3D Scaffolds🦴

Before a new technology or medical device can safely enter the market, extensive pre-clinical testing is required to investigate cellular and biological effects. To support this process, Ossiform developed 3D cell culture scaffolds produced using the same technology and material as our medical devices. These scaffolds were used in early in vitro and in vivo studies to demonstrate biological compatibility.

Recognizing a broader need for such systems within the academic bone research community, we made these scaffolds available to researchers around the world under the name P3D Scaffolds.

Since then, we have conducted multiple investigations, refined experimental protocols, generated robust datasets, and delivered thousands of scaffolds, enabling effective, translatable, bone-mimicking experimental models 🔬

The P3D Scaffolds are a classic example of how technology can bridge pre-clinical insights with clinical relevance and ultimately move innovations from bench to bedside.

In this short video clip from the recent online event “Bench to Bedside: Bioprinting Innovations” hosted by Jenny Chen from 3dheals , Ossiform’s CCO, Monica Wellejus, highlights key findings from our in-house investigations using P3D Scaffolds.

24/04/2026

Ossiform is pleased to announce that Gijs Klarenbeek, MD, has joined the company as Clinical- / Medical Affairs Advisor.

In this role, Gijs will support the continued strengthening of Ossiform’s clinical and medical affairs activities as the company prepares for launch and clinical adoption in the United States and initiates the studies to obtain the CE mark.

Gijs will contribute to the successful clinical implementation of Ossiform’s bio-integrative, 3D printed bone substitutes and surgical instrumentation across the U.S. and Europe. His work will focus on ensuring robust evidence generation and dissemination, supporting surgeon training and medical education, collaborating closely with key opinion leaders, CROs, and contributing to post-market regulatory and adoption activities.

23/04/2026

New publication alert! 📣

We are excited to share that our P3D Scaffolds are featured in a new, peer-reviewed publication, authored by Shweta Thapa, in ACS Omega:

Scaffold Material–Architecture Design Rules Linking Mechanics and Early Osteogenesis in PCL/β-TCP Grid, Honeycomb, and Gyroid Lattices (https://pubs.acs.org/doi/10.1021/acsomega.5c10393).

The article elucidates how material as well as scaffold architecture impacts scaffold mechanics and early osteogenesis by comparing PCL and β-tricalcium phosphate scaffolds with grid, gyroid, and honeycomb infill structures.

Here, the P3D Scaffolds supported robust cellular adhesion as well as early proliferation and osteogenesis due to the scaffold chemistry, which were enhanced when combined with gyroid and grid architecture. These findings highlight how scaffold design at the structural level can guide biological outcomes, which can be affected and supported by the material choice 🧬

Congratulation to Shweta for her great work on this paper!

17/04/2026

We are thrilled that Ossiform is part of the 2026 ABHI US Accelerator cohort, joining an amazing group of healthtech innovators.

This week marked the official kick-off, with the first bootcamp hosted at Wilson Sonsini's London offices. It was a great start to an ambitious program focused on supporting UK healthtech companies as they prepare to launch and scale in the US market.

We are looking forward to bringing Ossiform’s innovations to the US and to learning alongside such a strong cohort. More updates soon as our accelerator journey begins.

Thank you to the ABHI team and partners for the opportunity and for the warm welcome.

07/04/2026

What does it really take to bring bioprinting innovations from bench to bedside? 💡

This Thursday, Ossiform’s CCO, Monica Wellejus, will be speaking at the 3DHEALS webinar “Bench to Bedside: Bioprinting Innovations.”

Alongside bioprinting leaders and experts, Monica will share insights from Ossiform’s work in developing a new generation of 3D printed, bioactive bone substitutes. Drawing on experience across key stages of advancing the technology from early development toward clinical, commercial, and research applications, she brings a commercial perspective to the discussion.

In a newly published 3DHEALS interview, Monica highlighted one of the core challenges facing innovators in the field:

“One of the biggest challenges in 3D printing and bioprinting is that truly novel technologies rarely fit perfectly into existing frameworks. They often challenge established processes, definitions, and expectations.”

She will expand on this challenge, dive deeper into the technology, and share new data during the webinar on April 9th, at 5:00 PM CEST / 11:00 AM ET. Register here: https://3dheals.com/bench-to-bedside-bioprinting-innovations/

Join the conversation and gain insight into what it takes to move these technologies closer to patients 🏥

Read the rest of the interview: https://3dheals.com/from-hope-to-breakthrough-3d-printed-bone-regeneration-at-ossiform/

3dheals

17/03/2026

How can bone-mimicking scaffolds be used in cancer research? 🦴

While cancer research has come far with the use of traditional 2D cell cultures and various animal models, three-dimensional tumor models – also called tumoroids – are an emerging tool within the field.

Tumoroids have the ability to replicate key features of the tumor micro-environment, which in turn offer a more physiologically relevant disease model that retains the biological characteristics of the primary tumor🧫

Tumoroids are typically derived from patient cancer cells or immortalized cancer cell lines and they can enable:
- Studies of tumor-matrix interactions
- Evaluation of anticancer therapies
- Investigation of metastatic mechanisms

Many solid tumors and cancer types – including breast and prostate cancer – metastasize to our bones. Yet bone metastasis remains one of the most difficult aspects of cancer biology to model in vitro due to the complexity of the tissue.

By providing a mineralized, bone-mimicking microenvironment, the P3D Scaffolds from Ossiform enable researchers to grow 3D tumoroids that accurately replicate the tumor-host tissue interactions in a physiologically relevant setting without the use of animal models🐀

Such bone cancer model makes it possible to:
- Investigate how cancer cells colonize and adapt to bone
- Study metastatic mechanisms in a controlled system
- Screen anticancer therapies with improved translational relevance

As the field moves toward scalable, human-relevant research platforms, tumoroids represent a powerful alternative to traditional 2D cultures and many animal models.

Learn more about how P3D Scaffolds and tumoroids advance bone metastasis research and therapeutic development: https://ossiform.com/how-miniature-tumors-can-be-grown-on-p3d-scaffolds-for-cancer-research/

03/03/2026

Unboxing day! 📦

Exciting news from the team as we have just received our new 3D printer from !

Martin is especially happy today as we move this new addition into our cleanroom, where it will soon be used to print surgical instruments.

This upgrade marks an important step in expanding our production capabilities and leveraging 3D printing to meet clinical needs.

Adresse

Oslogade 1
Odense
5000

Telefon

+4553600670

Internet side

https://www.ossiform.com/

Underretninger

Vær den første til at vide, og lad os sende dig en email, når Ossiform sender nyheder og tilbud. Din e-mail-adresse vil ikke blive brugt til andre formål, og du kan til enhver tid afmelde dig.

Kontakt Virksomheden

Send en besked til Ossiform:

Genveje

Vil du plassere din virksomhed på toppen av Ingeniørvirksomhed-listen i Odense?

Del

Type

Videnskab, teknologi og ingeniørarbejde